Results for “FDA”

The Hill Eric Wargotz, opinion contributor Geopolitics

The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

Read at The Hill

BioPharma Dive Delilah Alvarado

Sanofi gains FDA clearance for Gaucher disease pill

The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.

Read at BioPharma Dive

BioPharma Dive Ben Fidler

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.

Read at BioPharma Dive

The Hill Lila Rose, opinion contributor Geopolitics

The FDA must stop dragging its feet and withdraw mifepristone for abortion

Every day of delay has consequences. Women like Herring and their unborn children deserve protection now — not more bureaucratic excuses and endless delays.

Read at The Hill

Ars Technica Beth Mole Tech policy

Trump abandons his FDA nominee, and Senate scraps vote on his NSF pick

"This time requires leadership and fortitude," Senator Bill Cassidy said.

Read at Ars Technica

STAT Biotech Margaret Manto

STAT+: 7 burning questions about the FDA’s post-Overton future

STAT tackles the most important questions about the FDA's uncertain future.

Read at STAT Biotech

BioPharma Dive Jonathan Gardner

White House pulls nomination for FDA nominee Overton

The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.

Read at BioPharma Dive

The Hill Ford McCracken Geopolitics

Cassidy questions 'odd' White House move in pulling FDA nominee

Sen. Bill Cassidy (R-La.) questioned the Trump administration’s reasoning for pulling Food and Drug Administration (FDA) commissioner nominee Heidi Overton, saying he thought she had the support needed to be confirmed. “Tonight, the White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the...

Read at The Hill

STAT Biotech Elaine Chen and Adam Feuerstein

STAT+: FDA discloses reasons for rejecting Summit drug

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

Read at STAT Biotech

BioPharma Dive BioPharma Dive staff

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

Read at BioPharma Dive

CBS News Politics Geopolitics

White House drops Heidi Overton's nomination for FDA commissioner

The White House has dropped the nomination of Dr. Heidi Overton, President Trump's pick for FDA commissioner, CBS News has confirmed.

Read at CBS News Politics

The Guardian US Politics Cecilia Nowell and agencies Geopolitics

White House withdraws nomination of Heidi Overton to lead FDA

Move to drop Trump ally and prominent abortion opponent comes a day before key Senate health committee vote The White House has dropped its nomination of Heidi Overton to lead the Food and Drug Administration, a White House official told the Guardian. Donald Trump nominated Overton – a physician and prominent abortion opponent – in August. Overton has spent most of her professional career working directly for Trump or conservative groups aligned with his agenda. Her…

Read at The Guardian US Politics

The Hill Nathaniel Weixel Geopolitics

White House pulls nomination of Heidi Overton to lead FDA

The White House withdrew the nomination of Heidi Overton to lead the Food and Drug Administration (FDA) amid opposition from Senate Republicans, it confirmed to The Hill. Overton was set to face a key vote Wednesday in the Senate health committee, where Republicans hold only a one-vote majority — meaning losing one member would be...

Read at The Hill

NBC News Berkeley Lovelace Jr. Geopolitics

White House drops Heidi Overton’s FDA nomination after Republicans raise concerns

The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday.

Read at NBC News

Axios Alex Isenstadt Geopolitics

Scoop: White House drops Heidi Overton's FDA nomination

The White House is dropping Heidi Overton's nomination to lead the Food and Drug Administration because of a lack of congressional support, Axios has learned. Why it matters: The decision means the Trump administration will have to find a new candidate to lead the FDA as HHS Secretary Robert F. Kennedy Jr. looks to advance his Make America Healthy Again agenda. "FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation," a senior…

Read at Axios

CBS News Politics Geopolitics

Trump FDA nominee Heidi Overton struggling to win GOP support

Heidi Overton, Trump's pick to be FDA commissioner, is having trouble finding enough Republican support to advance her nomination, which could be pulled if she falls short.

Read at CBS News Politics

BioPharma Dive Delilah Alvarado

Roche breast cancer pill cleared by FDA

Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

Read at BioPharma Dive

Green Queen (alternative protein) Anay Mridul

Upside Foods Launches New Cultivated Chicken at ‘Everyday Pricing’ with Second US Approval & 10,000x Scale-Up

13 Mins ReadUS cultivated meat leader Upside Foods has secured FDA and USDA clearance for its second-generation chicken, which it says is the industry’s first cultivated meat produced at large commercial scale. The halal-certified product, priced on par with premium organic chicken, is now on the menu at eight California restaurants and Stanford University, with chefs Thomas

Read at Green Queen (alternative protein)

Green Queen (alternative protein) Anay Mridul

Exclusive: Verley Opens US Arm, Hires Perfect Day Alum Ahead of 2027 Animal-Free Whey Launch

6 Mins ReadFrench precision fermentation startup Verley has opened a US branch and appointed Shayri Roychoudhury as its new COO as it ramps up production of its cow-free whey proteins for a mid-2027 launch. A year after securing a ‘no questions’ letter from the US Food and Drug Administration (FDA), Verley has now set up a new

Read at Green Queen (alternative protein)

STAT Biotech Margaret Manto

STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC

The supplement NAC has been widely available for years, but exists in a legal gray area.

Read at STAT Biotech

BioPharma Dive Jonathan Gardner

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

Read at BioPharma Dive

South China Morning Post Xinmei Shen Geopolitics

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise…

Read at South China Morning Post

The Hill Ryan Mancini Geopolitics

Cassidy says questions remain about Trump’s FDA pick ahead of committee vote

Sen. Bill Cassidy (R-La.) on Sunday said there are still questions left unanswered about President Trump's pick to lead the Food and Drug Administration (FDA), Dr. Heidi Overton, ahead of the Senate Health Committee's vote on her nomination this week. "Face the Nation" host Margaret Brennan asked Cassidy, the committee's chair, on CBS News if...

Read at The Hill

STAT Biotech Adam Feuerstein

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

Read at STAT Biotech

NBC News Tom Gottlieb

A seismic shakeup at Nvidia, and a Senate flip for the ages: The news quiz

The FDA issues a warning about GLP-1s, a soccer behemoth dumps its head coach, and this year’s Booker prize winner makes history.

Read at NBC News

arXiv (research papers) S M Rayeed SI

LABEL: Literature Asymmetry between Efficacy and Limits in Drug Knowledge and Language Models

Every medication comes with two types of medical facts: indications, which describe what conditions the drug treats (benefits), and contraindications, which describe who must avoid it to prevent serious harm (safety limits). Although contraindications are critical for patient safety and FDA regulations require listing them as rigorously as indications, we find that contraindications are far less documented than indications in general prose. In this paper, we measure how…

Read at arXiv (research papers)

The Hill Rob Taub Geopolitics

FDA issues recall for honey dietary supplement over undeclared ED ingredient

"The recall was initiated after FDA laboratory testing identified undeclared tadalafil," the notice said.

Read at The Hill

NBC News Berkeley Lovelace Jr. Geopolitics

Trump’s FDA pick faces Republican doubts as confirmation deadline nears

The FDA is set to finish its safety review of the abortion pill mifepristone in March, setting up one of the most politically charged decisions the agency has faced in years.

Read at NBC News

BioPharma Dive Kelly Bilodeau

The FDA has over 1k open jobs — and the staffing shortage is hitting pharma

The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

Read at BioPharma Dive

Nature Biotechnology Sojin Bing

A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

Read at Nature Biotechnology

Older stories